Oak Park, IL (January 5, 2010) – Siren Interactive, a relationship marketing agency focused on understanding the behaviors of patients and physicians dealing with chronic rare diseases, announces new hires. To support the influx of new business, in 2009 the company expanded in practically every department. A total of six new hires were added to the Siren team in Account Management, Project Management, Planning and Creative.
Oak Park, IL (January 26, 2010) – Siren Interactive Founder and President, Wendy White, is among the 18 women recently elected to the Board of Directors of the Healthcare Businesswomen’s Association (HBA). Members of the board are representative of the HBA’s diverse membership, which represents all aspects of the healthcare industry, from pharmaceutical and medical device companies to patient advocacy groups, healthcare communications and consulting firms across the US and Europe.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Feb 9, 2010 - Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended December 31, 2009, on Wednesday, February 17, 2010 at approximately 8:00 am Eastern Time (ET). The release will be followed by a live conference call, which will begin at approximately 10:00 am Eastern Time (ET) on Wednesday, February 17, 2010.
HASBROUCK HEIGHTS, NJ (February 9, 2010) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) provided an update today on the Company’s Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).
East Norriton, Penn., February 9, 2010 – Pharmaceutical companies are struggling with the transformative effect of digital media on every aspect of sales and marketing, finding new and diverse channels and sources of customer information, redefining “the customer” in the broadest possible context and developing actionable intelligence through it all. Jim Mercante, Partner, TGaS Advisors, together with Xavier Petit, Senior Manager, Consumer Database Marketing, Shire Pharmaceuticals, dealt with these issues at a recent Center for Business Intelligence (CBI) conference where they spoke on the topic, “Integrating Customer Relationship Management and New Sources of Customer Focused Data.”
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced a turnover of of €7.5 million for 2009.
GREAT NECK, N.Y.--(BUSINESS WIRE)--Feb 9, 2010 - Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company's first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Feb 9, 2010 - Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company in the US, is pleased to announce it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market.
ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) , a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced it will release results for the fourth quarter and full year ended December 31, 2009, on Tuesday, February 16, 2010, before the market opens. A full text copy of the release will be disseminated at that time.
CAMBRIDGE, Mass., Feb. 9 /PRNewswire/ -- Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
TALLAHASSEE, Fla., Feb. 9 /PRNewswire/ -- LearnSomething Inc., a leader in eLearning products and services for food, drug and mass retailers, today announced that Phil Keough, President of Keoco, LLC, a leading pharmacy management consulting company, has joined LearnSomething's senior management as Chief Business Development Officer.
LAUSANNE, Switzerland, February 9/PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect.
Basel, February 9, 2010 - Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.
NEWTON, Mass.--(BUSINESS WIRE)--Feb 9, 2010 - Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company's operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter.
CONCORD, Calif.--(BUSINESS WIRE)--Feb 9, 2010 - Cerus Corporation (NASDAQ:CERS) announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion.
GERMANTOWN, Md.--(BUSINESS WIRE)--Feb 9, 2010 - Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND).
TEL AVIV, Israel--(BUSINESS WIRE)--Feb 9, 2010 - Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year ending December 31, 2009.
MONROVIA, Calif.--(BUSINESS WIRE)--Feb 9, 2010 - Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Edgardo Baracchini, Ph.D., to chief business officer.
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb 9, 2010 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the appointment of Jeffrey W. Winkelman, Ph.D., J.D. as vice president, oncology programs. His primary responsibilities will be management of BioSante's oncology products including collaborations with John Hopkins Sidney Kimmel Cancer Center, contracts, licensing and intellectual property.
SAN DIEGO--(BUSINESS WIRE)--Feb 9, 2010 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced financial results for the three and 12 months ended December 31, 2009, and reviewed business highlights of the fourth quarter of 2009 and early 2010.
|
